The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis
| dc.contributor.author | Kınıklı, Gülay | |
| dc.contributor.authorID | http://orcid.org/0000-0002-4006-1022 | tr_TR |
| dc.contributor.department | Tıp Fakültesi | tr_TR |
| dc.date.accessioned | 2020-03-17T07:29:01Z | |
| dc.date.available | 2020-03-17T07:29:01Z | |
| dc.date.issued | 2007 | |
| dc.description.abstract | Objectives: To investigate the role of shared epitope (SE) alleles in the short-term clinical response to leflunomide for the treatment of active RA. Methods: In an open-label, multi-centre study of 16-weeks duration, 93 patients (82% female) fulfilling ARA 1987 RA criteria were treated with leflunomide (100 mg loading dose for 3 days, then 20 mg/day as the maintenance dose). The primary efficacy criterion was the response status according to the European League Against Rheumatism (EULAR) response criteria using Disease Activity Score-28 (DAS28) activity measure. SE determinations have been undertaken by polymerase chain reaction and sequence-specific oligonucleotide genotyping methods. Results: The mean (s.d.) Disease Activity Score-28 (DAS28) was 5.1 (1.3) before the treatment, which was significantly decreased after 16 weeks [3.0 (1.1), P < 0.001]. According to the EULAR response criteria, 55 patients (59.1%) were classified as good responders. SE was positive in 51 (54.8%) of the patients, with 13 (13.9%) having SE homozygosity or carrying any two SE alleles. Among SE-positive patients, 68.6% (35/51) were good responders, compared with 47.6% (20/42) in SE negatives (P = 0.04). No difference was present according to SE hetero- or homozygosity (68.4 vs 69.2%). RF was also present significantly more frequently in the SE-positive group compared with negatives (78.4 vs 57.1%, P = 0.03). However, no significant difference was observed in the prevalence of RF positivity in patients with a good clinical response (72.7 vs 63.2%, P = 0.32). Conclusions: The results suggest that HLA-DRB1 SE presence may favourably affect the outcome of leflunomide monotherapy in an unselected group of RA patients with an active disease and naive to leflunomide. © The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. | tr_TR |
| dc.description.index | Scopus | |
| dc.description.index | Pubmed | |
| dc.identifier.endpage | 1844 | tr_TR |
| dc.identifier.issn/e-issn | 14620324 | |
| dc.identifier.issue | 12 | tr_TR |
| dc.identifier.startpage | 1842 | tr_TR |
| dc.identifier.uri | https://doi.org/10.1093/rheumatology/kem278 | tr_TR |
| dc.identifier.uri | http://hdl.handle.net/20.500.12575/70673 | |
| dc.identifier.volume | 46 | tr_TR |
| dc.language.iso | en | tr_TR |
| dc.relation.isversionof | 10.1093/rheumatology/kem278 | tr_TR |
| dc.relation.journal | Rheumatology | tr_TR |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | tr_TR |
| dc.subject | Leflunomide | tr_TR |
| dc.subject | Rheumatoid arthritis | tr_TR |
| dc.subject | Shared epitope | tr_TR |
| dc.title | The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis | tr_TR |
| dc.type | Article | tr_TR |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- The-role-of-HLADRB1-shared-epitope-alleles-in-predicting-shortterm-response-to-leflunomide-in-rheumatoid-arthritis2007Rheumatology.pdf
- Size:
- 106.29 KB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.62 KB
- Format:
- Item-specific license agreed upon to submission
- Description: